Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma

Oncotarget

Volumn 6, Issue 38, 2015, Pages 41134-41145

  Laurinavicius, Arvydas ^a   Green, Andrew R ^b   Laurinaviciene, Aida ^a   Smailyte, Giedre ^a,c   Ostapenko, Valerijus ^c   Meskauskas, Raimundas ^a   Ellis, Ian O ^b  

^a VILNIUS UNIVERSITY   (Lithuania)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c National Cancer Institute   (Lithuania)

Author keywords

Breast cancer; Digital image analysis; HIF 1 ; Immunohistochemistry; SATB1

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; MARKER; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P16; PROTEIN P53; SATB1 PROTEIN; UNCLASSIFIED DRUG; MATRIX ATTACHMENT REGION BINDING PROTEIN; SATB1 PROTEIN, HUMAN; STEROID RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; KI67 SATB1 RATIO; MAJOR CLINICAL STUDY; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; TISSUE MICROARRAY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; OUTCOME ASSESSMENT; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; TUMOR INVASION;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MATRIX ATTACHMENT REGION BINDING PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTORS, STEROID; SURVIVAL ANALYSIS;

EID: 84951011334     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5838     Document Type: Article

References (38)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
2. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol. 2011; 22:1736-1747.
3. Prat A, Ellis MJ, Perou CM. Practical implications of geneexpression-based assays for breast oncologists. Nat Rev Clin Oncol. 2011; 9:48-57.
4. Esposito A, Criscitiello C, Curigliano G. Highlights from the 14(th) St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer. Ecancermedicalscience. 2015; 9:518.
5. Rakha EA, Ellis IO. Modern classification of breast cancer: should we stick with morphology or convert to molecular profile characteristics. Adv Anat Pathol. 2011; 18:255-267.
6. Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, Zabaglo L, Mallon E, Green AR, Ellis IO, Howell A, Buzdar AU, Forbes JF. Prognostic value of a combined estrogen receptor, progesterone receptor, ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol. 2011; 29:4273-4278.
7. Barton S, Zabaglo L, A'Hern R, Turner N, Ferguson T, O'Neill S, Hills M, Smith I, Dowsett M. Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. Br J Cancer. 2012; 106:1760-1765.
8. Afentakis M, Dowsett M, Sestak I, Salter J, Howell T, Buzdar A, Forbes J, Cuzick J. Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study. Breast Cancer Res Treat. 2013; 140:253-262.
9. Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, Erlander MG, Dunbier A, Sidhu K, Lopez-Knowles E, Goss PE, Dowsett M. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. 2013; 14:1067-1076.
10. Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, Ferree S, Storhoff J, Schaper C, Cuzick J. Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy. J Clin Oncol. 2013; 31:2783-2790.
11. Rakha EA, Reis-Filho JS, Ellis IO. Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat. 2010; 120:293-308.
12. Soria D, Garibaldi JM, Ambrogi F, Green AR, Powe D, Rakha E, Macmillan RD, Blamey RW, Ball G, Lisboa PJ, Etchells TA, Boracchi P, Biganzoli E, Ellis IO. A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients. Comput Biol Med. 2010; 40:318-330.
13. Tadrous PJ. On the concept of objectivity in digital image analysis in pathology. Pathology. 2010; 42:207-211.
14. Heindl A, Nawaz S, Yuan Y. Mapping spatial heterogeneity in the tumor microenvironment: a new era for digital pathology. Lab Invest. 2015; 95:377-384.
15. Carvajal-Hausdorf DE, Schalper KA, Neumeister VM, Rimm DL. Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic. Lab Invest. 2015; 95:385-396.
16. Laurinavicius A, Laurinaviciene A, Ostapenko V, Dasevicius D, Jarmalaite S, Lazutka J. Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data. Diagn Pathol. 2012; 7:27.
17. Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, Denkert C. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One. 2012; 7:e51862.
18. Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 2008; 452:187-193.
19. Patani N, Jiang W, Mansel R, Newbold R, Mokbel K. The mRNA expression of SATB1 and SATB2 in human breast cancer. Cancer Cell Int. 2009; 9:18.
20. Yamayoshi A, Yasuhara M, Galande S, Kobori A, Murakami A. Decoy-DNA against special AT-rich sequence binding protein 1 inhibits the growth and invasive ability of human breast cancer. Oligonucleotides. 2011; 21:115-121.
21. Hanker LC, Karn T, Mavrova-Risteska L, Ruckhaberle E, Gaetje R, Holtrich U, Kaufmann M, Rody A, Wiegratz I. SATB1 gene expression and breast cancer prognosis. Breast. 2011; 20:309-313.
22. Kohwi-Shigematsu T, Han HJ, Russo J, Kohwi Y. Re: The role of SATB1 in breast cancer pathogenesis. J Natl Cancer Inst. 2010; 102:1879-1880. author reply 1880-1871.
23. Iorns E, Hnatyszyn HJ, Seo P, Clarke J, Ward T, Lippman M. The role of SATB1 in breast cancer pathogenesis. J Natl Cancer Inst. 2010; 102:1284-1296.
24. Heubner M, Kimmig R, Aktas B, Siffert W, Frey UH. The haplotype of three polymorphisms in the promoter region impacts survival in breast cancer patients. Oncology letters. 2014; 7:2007-2012.
25. Kobierzycki C, Wojnar A, Dziegiel P. Expression of SATB1 protein in the ductal breast carcinoma tissue microarrays-preliminary study. Folia Histochem Cytobiol. 2013; 51:333-338.
26. Liu X, Zheng Y, Qiao C, Qv F, Wang J, Ding B, Sun Y, Wang Y. Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics. Diagn Pathol. 2015; 10:50.
27. Brocato J, Costa M. SATB1 and 2 in colorectal cancer. Carcinogenesis. 2015; 36:186-191.
28. Selinger CI, Cooper WA, Al-Sohaily S, Mladenova DN, Pangon L, Kennedy CW, McCaughan BC, Stirzaker C, Kohonen-Corish MR. Loss of Special AT-Rich Binding Protein 1 Expression is a Marker of Poor Survival in Lung Cancer. J Thorac Oncol. 2011; 6:1179-1189.
29. Elebro J, Heby M, Gaber A, Nodin B, Jonsson L, Fristedt R, Uhlen M, Jirstrom K, Eberhard J. Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma. Journal of translational medicine. 2014; 12:289.
30. Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nature reviews Cancer. 2011; 12:9-22.
31. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res. 2002; 8:1831-1837.
32. Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer. 2003; 97:1573-1581.
33. Yamamoto Y, Ibusuki M, Okumura Y, Kawasoe T, Kai K, Iyama K, Iwase H. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat. 2008; 110:465-475.
34. Dales JP, Beaufils N, Silvy M, Picard C, Pauly V, Pradel V, Formisano-Treziny C, Bonnier P, Giusiano S, Charpin C, Gabert J. Hypoxia inducible factor 1alpha gene (HIF-1alpha) splice variants: potential prognostic biomarkers in breast cancer. BMC medicine. 2010; 8:44.
35. Vleugel MM, Greijer AE, Shvarts A, van der Groep P, van Berkel M, Aarbodem Y, van Tinteren H, Harris AL, van Diest PJ, van der Wall E. Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol. 2005; 58:172-177.
36. Rundqvist H, Johnson RS. Tumour oxygenation: implications for breast cancer prognosis. Journal of internal medicine. 2013; 274:105-112.
37. Wockel A, Wolters R, Wiegel T, Novopashenny I, Janni W, Kreienberg R, Wischnewsky M, Schwentner L. The impact of adjuvant radiotherapy on the survival of primary breast cancer patients: a retrospective multicenter cohort study of 8935 subjects. Ann Oncol. 2014; 25:628-632.
38. Konig J, van Ewijk R, Kuhr K, Schmidberger H, Wockel A, Kreienberg R, Blettner M. Radiotherapy effects on early breast cancer survival in observational and randomized studies: a systematic analysis of advantages, disadvantages and differences between the two study types. Breast Cancer. 2015. [Epub ahead of print]